Vaccine effectiveness of the pneumococcal polysaccharide and conjugated vaccines in elderly and high-risk populations in preventing invasive pneumococcal disease: a systematic search and meta-analysis
- PMID: 36698750
- PMCID: PMC9870017
- DOI: 10.1080/20018525.2023.2168354
Vaccine effectiveness of the pneumococcal polysaccharide and conjugated vaccines in elderly and high-risk populations in preventing invasive pneumococcal disease: a systematic search and meta-analysis
Abstract
Background: Invasive pneumococcal disease (IPD) is a major cause of morbidity and mortality globally. However, the literature on the vaccine effectiveness (VE) of 23-valent polysaccharide vaccine (PPV23) and 13-valent conjugated vaccine (PCV13) against IPD in adults is sparse. The aim was to summarize the available evidence on the VE of the PPV23 and the PCV13 in elderly individuals against IPD and to investigate how age and comorbidities influence VE against IPD.
Methods: A systematic search was conducted in Medline and Embase in February 2021. We used combinations of terms related to PPV23, PCV13, elderly, high-risk populations, and IPD. Eligible articles published since 2010 were included. Two authors reviewed and extracted data.
Results: Eight studies met the inclusion criteria for PPV23. The meta-analysis showed a reduced OR for all-type IPD with the use of PPV23 vaccine compared with unvaccinated controls (OR 0.69; 95%CI 0.54, 0.88) and a reduced OR for vaccine-type IPD compared with non-vaccine type IPD (0.69; 95%CI 0.63, 0.76). VE against vaccine-type IPD ranged from 28% to 54.1% for individuals aged 65-79 and from 7.5% to 34% for those aged ≥80-85 years. Most studies found a lower VE of PPV23 in populations with comorbidities and in immunocompromised populations compared with the VE for individuals without comorbidities.One study met the inclusion criteria for PCV13. The vaccine efficacy of PCV13 against IPD in individuals aged ≥65 was 75.0% (95% CI, 41.4 to 90.8).
Conclusion: The results from this review show a reduction of IPD in elderly and high-risk populations vaccinated with PPV23 and PCV13. The protective effect may be lower in elderly individuals aged >80 and in individuals with comorbidities. However, the literature is sparse; large-scale prospective studies are required to evaluate the VE of PPV23 and PCV13 vaccination in adults against IPD.
Keywords: 13-valent conjugated vaccine; 23-valent pneumococcal polysaccharide vaccine; Streptococcus pneumoniae; elderly; invasive pneumococcal disease; review; vaccine effectiveness.
© 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
Conflict of interest statement
No potential conflict of interest was reported by the authors.
Figures


Similar articles
-
Pneumococcal Vaccination in Adults: What Can We Learn From Observational Studies That Evaluated PCV13 and PPV23 Effectiveness in the Same Population?Arch Bronconeumol. 2023 Mar;59(3):157-164. doi: 10.1016/j.arbres.2022.12.015. Epub 2023 Jan 7. Arch Bronconeumol. 2023. PMID: 36681604 Review. English, Spanish.
-
Direct effectiveness of pneumococcal polysaccharide vaccine against invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia in elderly population in the era of pneumococcal conjugate vaccine: A case-control study.Vaccine. 2019 May 9;37(21):2797-2804. doi: 10.1016/j.vaccine.2019.04.017. Epub 2019 Apr 17. Vaccine. 2019. PMID: 31005428
-
Application of the screening and indirect cohort methods to evaluate the effectiveness of pneumococcal vaccination program in adults 75 years and older in Taiwan.BMC Infect Dis. 2021 Jan 10;21(1):45. doi: 10.1186/s12879-020-05721-0. BMC Infect Dis. 2021. PMID: 33423657 Free PMC article.
-
Pneumococcal vaccine uptake and vaccine effectiveness in older adults with invasive pneumococcal disease in Germany: A retrospective cohort study.Lancet Reg Health Eur. 2021 Jun 3;7:100126. doi: 10.1016/j.lanepe.2021.100126. eCollection 2021 Aug. Lancet Reg Health Eur. 2021. PMID: 34557837 Free PMC article.
-
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to 23-valent pneumococcal polysaccharide in immunocompetent adults: A systematic review and meta-analysis.Vaccine. 2019 Feb 14;37(8):1021-1029. doi: 10.1016/j.vaccine.2019.01.014. Epub 2019 Jan 23. Vaccine. 2019. PMID: 30685252
Cited by
-
Vaccine uptake, associated factors and reasons for vaccination status among the South African elderly; findings and next steps.PLoS One. 2024 Dec 4;19(12):e0314098. doi: 10.1371/journal.pone.0314098. eCollection 2024. PLoS One. 2024. PMID: 39630746 Free PMC article.
-
Vaccines for the Elderly and Vaccination Programs in Europe and the United States.Vaccines (Basel). 2024 May 22;12(6):566. doi: 10.3390/vaccines12060566. Vaccines (Basel). 2024. PMID: 38932295 Free PMC article. Review.
-
Follow-Up Study of Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against All-Type and Serotype-Specific Invasive Pneumococcal Disease, Denmark.Emerg Infect Dis. 2024 Jun;30(6):1164-1172. doi: 10.3201/eid3006.230975. Emerg Infect Dis. 2024. PMID: 38781925 Free PMC article.
-
Attitudes Toward General Vaccination Mediate the Association Between Influenza Vaccination History and Pneumococcal Vaccination Intention Among Older Adults in China.Vaccines (Basel). 2024 Dec 29;13(1):20. doi: 10.3390/vaccines13010020. Vaccines (Basel). 2024. PMID: 39852799 Free PMC article.
-
World Pneumonia Day: Why Do We Still Need It?Am J Respir Crit Care Med. 2024 Dec 1;210(11):1297-1299. doi: 10.1164/rccm.202410-1883VP. Am J Respir Crit Care Med. 2024. PMID: 39530684 Free PMC article. No abstract available.
References
-
- GBD . Lower respiratory infections collaborators, “Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the global burden of disease study 2016 (in eng). Lancet Infect Dis. 2016. Nov;18(11):1191–10. DOI:10.1016/s1473-3099(18)30310-4 - DOI - PMC - PubMed
-
- Andrews EANJ. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine. 2012;30(48):6802–6808. - PubMed
-
- Niederman MS, Folaranmi T, Buchwald UK, et al. Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and noninvasive pneumococcal disease and related outcomes: a review of available evidence. Expert Rev Vaccines. 2021;20(3):1–13. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous